Rapid Micro Biosystems, Inc.
NASDAQ:RPIDMedical - Devices
+$0.03 today
- Market cap
- $50.31M
- Beta
- 1.46
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$1.10
Volume 0.17M
Average 0.18M
RPID Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Rapid Micro Biosystems, Inc.NASDAQ: RPID
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q1 FY2026 revenue of $8M rose 11.1% year over year, behind the +16.0% change in trailing-twelve-month revenue. Sequentially, it fell 29.1% from the prior quarter. Over 3 fiscal years it compounded at +25.2% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $39.33M (+17.1%) for the fiscal year ending Dec 2026, a slowdown from the +19.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $8M-29.1% QoQ
- Last fiscal yearDec 2025
- $33.59M+19.7% YoY
- LTMMar 2026
- $34.38M+16.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.1% | +8.4% | -2.6 pp |
| 1 year | +19.7% | +17.1% | -2.7 pp |
| 3-year CAGR | +25.2% | +24.6% | -0.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 33.59M USD
- Year-over-year change
- +19.7%
- 4-year CAGR
- +9.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.59M | +19.7% |
| FY2024 | 2024-12-31 | 28.05M | +24.6% |
| FY2023 | 2023-12-31 | 22.52M | +31.4% |
| FY2022 | 2022-12-31 | 17.13M | -26.3% |
| FY2021 | 2021-12-31 | 23.23M | — |
Revenue vs competitors
How RPID compares with its peers on the latest reported figures
- RPID's LTM Mar 2026 revenue of $34.38M is the 5th highest of the 9 companies compared; the peer median is $30.52M.
- Its year-over-year change of +16.0% is the 4th highest of 7, against a peer median of +9.7%.
- Over three fiscal years its annual growth of +25.2% compares with a peer median of +16.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $107.06M | +26.8% | +15.2% | |
| LTM Mar 2026 | $72.35M | +1.0% | +27.7% | |
| LTM Mar 2026 | $57.7M | +1.1% | +18.2% | |
| LTM Mar 2026 | $55.9M | +18.2% | +5.9% | |
| LTM Mar 2026 | $34.38M | +16.0% | +25.2% | |
| LTM Mar 2026 | $5.13M | +23.0% | +132.0% | |
| LTM Mar 2026 | $57K | -50.4% | -32.9% | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| Peer median (excluding RPID) | $30.52M | +9.7% | +16.7% | |
Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.23M | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | 30.97M | 25.67M | 28M | 28.16M | 25.98M |
| Gross Profit | (7.74M) | (8.54M) | (5.49M) | (109K) | 7.61M |
| Gross Margin | -33.3% | -49.8% | -24.4% | -0.4% | 22.7% |
| Research & Development | 9.78M | 12.87M | 12.82M | 14.6M | 13.6M |
| Selling, General & Admin | 29.71M | 41.81M | 38.26M | 35.21M | 34.84M |
| Operating Expenses | 39.49M | 54.68M | 51.08M | 49.81M | 55M |
| Depreciation & Amortization | 1.53M | 2.84M | 3.11M | 3.36M | 3.25M |
| EBITDA | (69.25M) | (58.55M) | (49.33M) | (43.51M) | (42.74M) |
| EBITDA Margin | -298.1% | -341.7% | -219.1% | -155.1% | -127.3% |
| Operating Income | (47.23M) | (63.22M) | (56.56M) | (49.92M) | (47.39M) |
| Operating Margin | -203.3% | -369.0% | -251.2% | -178.0% | -141.1% |
| Interest Income | 0 | 1.78M | 4.21M | 3.16M | 1.51M |
| Interest Expense | 2.65M | 0 | 0 | 0 | 1.09M |
| Other Income / Expenses | (26.2M) | 1.84M | 4.13M | 3.05M | 309K |
| Income Before Tax | (73.43M) | (61.38M) | (52.44M) | (46.87M) | (47.08M) |
| Pre-Tax Margin | -316.1% | -358.3% | -232.9% | -167.1% | -140.2% |
| Income Tax Expense | 91K | (576K) | 31K | 22K | 40K |
| Net Income | (73.52M) | (60.81M) | (52.47M) | (46.89M) | (47.12M) |
| Net Margin | -316.5% | -354.9% | -233.0% | -167.2% | -140.3% |
| EPS (Basic) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| EPS (Diluted) | (1.88) | (1.43) | (1.22) | (1.08) | (1.05) |
| Weighted Avg Shares | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
| Weighted Avg Shares (Diluted) | 41.47M | 42.45M | 43.02M | 43.58M | 44.68M |
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
Intrinsic Alpha fair value
Locked
Current Price
$1.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.